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Background:  Galectin-3 is a prognostic heart failure (HF) biomarker associated with aldosterone-induced myocardial fibrosis. 
Mineralocorticoid receptor antagonists (MRA) may reduce such fibrosis. We sought to examine the outcomes of patients with HF with 
reduced ejection fraction (HFrEF) as a function of galectin-3 concentrations and MRA therapy.
methods:  Galectin-3 concentrations were measured at baseline in 151 patients with chronic HFrEF in the Pro-BNP Outpatient Tailored 
Chronic HF Therapy (PROTECT) study who were followed over a mean of 10 months. Patients were categorized by baseline galectin-3 
and subsequent MRA addition or intensification; outcomes assessed included cardiovascular (CV) events, left ventricular remodeling, 
safety and change in quality of life.
results:  Concentrations of galectin-3 >20 ng/mL were associated with doubling in adjusted risk for CV events, regardless of MRA 
treatment. In patients with elevated galectin-3 who were subsequently treated with more intensive MRA therapy, there was no significant 
difference in CV event rates (P=0.76) or the cumulative number of such events (P= 0.74). In adjusted analysis, no difference in time to 
first CV event was seen if MRA was added or intensified in those with a high galectin-3 (HR=0.99, 95% CI=0.97-1.02, P=0.74); cumulative 
MRA dose was also not a specific predictor of benefit in those with galectin-3 >20 ng/mL. In subjects with elevated galectin-3 values, MRA 
therapy did not specifically improve left ventricular remodeling indices or quality of life at follow-up. Rates of treatment-related adverse 
events were highest in those with elevated galectin-3 treated with more intensive MRA use. Elevated galectin-3 was associated with more 
significant renal dysfunction, but this was unaffected by MRA use.
conclusion:  Among patients with chronic HFrEF, galectin-3 provided prognostic information, but we found no specific interaction between 
addition or intensification of MRA therapy and elevated galectin-3. Further studies are needed to determine if galectin-3 can be employed 
to “personalize” HF therapy.
